Auto-antibodies to p53 and the Subsequent Development of Colorectal Cancer in a U.S. Prospective Cohort Consortium.
Journal
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
ISSN: 1538-7755
Titre abrégé: Cancer Epidemiol Biomarkers Prev
Pays: United States
ID NLM: 9200608
Informations de publication
Date de publication:
12 2020
12 2020
Historique:
received:
20
05
2020
revised:
01
08
2020
accepted:
21
09
2020
pubmed:
26
9
2020
medline:
22
12
2021
entrez:
25
9
2020
Statut:
ppublish
Résumé
Auto-antibodies to tumor suppressor p53 are found in a subset of patients with colorectal cancer. A recent prospective study in the United States has reported a significant 1.8-fold increased odds for colorectal cancer development with prediagnostic seropositivity to p53. In this study, we sought to examine this association in a U.S. colorectal cancer cohort consortium to evaluate the potential utility of p53 auto-antibodies as an early biomarker for colorectal cancer. Auto-antibodies to p53 were measured in prediagnostic blood samples of 3,702 incident colorectal cancer cases and 3,702 controls, matched by age, race, and sex, from 9 U.S. prospective cohorts. The association of seropositivity to p53 with colorectal cancer risk, overall and by time between blood draw and diagnosis, was determined by conditional logistic regression. Overall, 5% of controls and 7% of cases were seropositive to p53, resulting in a statistically significant 33% increased colorectal cancer risk [odds ratio (OR), 1.33; 95% confidence interval (CI), 1.09-1.61]. By follow-up time, the association was only significant with colorectal cancer diagnoses within 4 years after blood draw (OR, 2.27; 95% CI, 1.62-3.19), but not thereafter (OR, 0.97; 95% CI, 0.76-1.24). In this large consortium of prospective cohorts, we found that prediagnostic seropositivity to tumor suppressor p53 was significantly associated with an over 2-fold increased odds of developing colorectal cancer within 4 years after blood draw. Our finding suggests that p53 seropositivity may not be a useful predictor of long-term colorectal cancer risk; however, it might be considered as a marker to aid in the early diagnosis of colorectal cancer.
Sections du résumé
BACKGROUND
Auto-antibodies to tumor suppressor p53 are found in a subset of patients with colorectal cancer. A recent prospective study in the United States has reported a significant 1.8-fold increased odds for colorectal cancer development with prediagnostic seropositivity to p53. In this study, we sought to examine this association in a U.S. colorectal cancer cohort consortium to evaluate the potential utility of p53 auto-antibodies as an early biomarker for colorectal cancer.
METHODS
Auto-antibodies to p53 were measured in prediagnostic blood samples of 3,702 incident colorectal cancer cases and 3,702 controls, matched by age, race, and sex, from 9 U.S. prospective cohorts. The association of seropositivity to p53 with colorectal cancer risk, overall and by time between blood draw and diagnosis, was determined by conditional logistic regression.
RESULTS
Overall, 5% of controls and 7% of cases were seropositive to p53, resulting in a statistically significant 33% increased colorectal cancer risk [odds ratio (OR), 1.33; 95% confidence interval (CI), 1.09-1.61]. By follow-up time, the association was only significant with colorectal cancer diagnoses within 4 years after blood draw (OR, 2.27; 95% CI, 1.62-3.19), but not thereafter (OR, 0.97; 95% CI, 0.76-1.24).
CONCLUSIONS
In this large consortium of prospective cohorts, we found that prediagnostic seropositivity to tumor suppressor p53 was significantly associated with an over 2-fold increased odds of developing colorectal cancer within 4 years after blood draw.
IMPACT
Our finding suggests that p53 seropositivity may not be a useful predictor of long-term colorectal cancer risk; however, it might be considered as a marker to aid in the early diagnosis of colorectal cancer.
Identifiants
pubmed: 32972968
pii: 1055-9965.EPI-20-0780
doi: 10.1158/1055-9965.EPI-20-0780
pmc: PMC7710535
mid: NIHMS1632879
doi:
Substances chimiques
Autoantibodies
0
TP53 protein, human
0
Tumor Suppressor Protein p53
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
2729-2734Subventions
Organisme : NHLBI NIH HHS
ID : HHSN268201600002C
Pays : United States
Organisme : NHLBI NIH HHS
ID : HHSN268201600018C
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA182934
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA190428
Pays : United States
Organisme : NHLBI NIH HHS
ID : HHSN268201600003C
Pays : United States
Organisme : NCI NIH HHS
ID : UM1 CA186107
Pays : United States
Organisme : NHLBI NIH HHS
ID : HHSN268201600004C
Pays : United States
Organisme : NHLBI NIH HHS
ID : HHSN268201600001C
Pays : United States
Organisme : NCI NIH HHS
ID : UM1 CA167552
Pays : United States
Organisme : NCI NIH HHS
ID : R00 CA215314
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA040360
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA077955
Pays : United States
Organisme : NCI NIH HHS
ID : P01 CA087969
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL034595
Pays : United States
Organisme : NIDDK NIH HHS
ID : P30 DK058404
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA092447
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA167552
Pays : United States
Organisme : NCI NIH HHS
ID : UM1 CA182934
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK058587
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA202979
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA097193
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA071789
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA164973
Pays : United States
Informations de copyright
©2020 American Association for Cancer Research.
Références
Cancer Lett. 2014 May 1;346(2):178-87
pubmed: 24462820
Nat Rev Immunol. 2017 Jan;17(1):21-29
pubmed: 27916977
Clin Gastroenterol Hepatol. 2015 Aug;13(8):1472-9
pubmed: 25724708
Am J Gastroenterol. 2008 Jun;103(6):1541-9
pubmed: 18479499
Clin Chem. 2005 Oct;51(10):1845-53
pubmed: 16099939
CA Cancer J Clin. 2017 May 6;67(3):177-193
pubmed: 28248415
Oncotarget. 2016 Mar 29;7(13):16420-32
pubmed: 26909861
Gastroenterology. 2019 Jan;156(1):175-186.e2
pubmed: 30296434
Clin Gastroenterol Hepatol. 2019 Aug;17(9):1829-1839.e4
pubmed: 30851476
Eur J Cancer Prev. 1999 Dec;8 Suppl 1:S39-47
pubmed: 10772417
Cancer Res. 1990 Dec 1;50(23):7717-22
pubmed: 2253215
Oncol Lett. 2018 Apr;15(4):5489-5496
pubmed: 29556296
Cancer Res. 2000 Apr 1;60(7):1777-88
pubmed: 10766157
Clin Cancer Res. 2016 Apr 1;22(7):1725-33
pubmed: 26561557
Cancer Epidemiol Biomarkers Prev. 2018 Oct;27(10):1186-1194
pubmed: 30038049
BMJ. 2014 Apr 09;348:g2467
pubmed: 24922745
Nat Rev Gastroenterol Hepatol. 2011 Nov 01;8(12):711-22
pubmed: 22045159
Clin Cancer Res. 2001 May;7(5):1118-26
pubmed: 11350874
Nat Rev Cancer. 2009 Oct;9(10):701-13
pubmed: 19693097
Br J Cancer. 2013 Jan 15;108(1):107-14
pubmed: 23169294
Eur J Cancer. 2013 Sep;49(14):3049-54
pubmed: 23706981
Cancer Epidemiol Biomarkers Prev. 2018 Feb;27(2):219-223
pubmed: 29254936